Top

Published in:

Open Access 01-12-2014 | Research article

Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis

Authors: Shunji Nakatake, Shigeo Yoshida, Shintaro Nakao, Ryoichi Arita, Miho Yasuda, Takeshi Kita, Hiroshi Enaida, Yuji Ohshima, Tatsuro Ishibashi

Published in: BMC Ophthalmology | Issue 1/2014

Abstract

Background

Several retinal ischemic diseases can cause neovascular glaucoma (NVG). Trabeculectomy with mitomycin C (MMC) is a relatively better treatment modality in the management of eyes with NVG than other glaucoma surgeries. The aim of this study was to investigate the factors that may influence the outcome of trabeculectomy with MMC for NVG.

Methods

Forty-nine NVG eyes from 43 patients (26 males and 17 females) underwent primary trabeculectomy with MMC. The mean follow-up period was 16.8 ± 8.1 months (range, 6 to 34 months). Twenty-one eyes of 21 patients received intravitreal bevacizumab (IVB) 3.6 ± 1.8 days before trabeculectomy with MMC. A Kaplan-Meier survival-curve analysis was used to summarize the cumulative probability of success. We examined the relationship between the surgical outcome and the following surgical factors: gender, age, history of panretinal photocoagulation, history of cataract surgery, history of vitrectomy, preoperative IVB, NVG in the fellow eye, and postoperative complications (hyphema, choroidal detachment, and formation of fibrin) by multivariate analysis.

Results

The survival rate was 83.7% after 6 months, 70.9% after 12 months, and 60.8% after 24 months. The Kaplan-Meier survival curves showed no significant difference in the survival rate between the eyes with preoperative IVB (n = 21) and the eyes without preoperative IVB (n = 28) (p = 0.14). The multiple logistic regression analysis showed that postoperative hyphema (odds ratio, 6.54; 95% confidence interval, 1.41 to 35.97) was significantly associated with the surgical outcome (p = 0.02).

Conclusions

Postoperative hyphema was significantly correlated with the outcome of trabeculectomy for NVG. There was no significant association between preoperative IVB and postoperative hyphema or the results of trabeculectomy.

Available only for authorised users

Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Napoleone F, King GL: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994, 331: 1480-1487. 10.1056/NEJM199412013312203.CrossRefPubMed

Mandal AK, Majji AB, Mandal SP, Das T, Jalali S, Gothwal VK, Jain SS, Nutheti R: Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report. Indian J Ophthalmol. 2002, 50: 287-293.PubMed

Kiuchi Y, Sugimoto R, Nakae K, Saito Y, Ito S: Trabeculectomy with mitomycin C for treatment of neovascular glaucoma in diabetic patients. Ophthalmologica. 2006, 220: 383-388. 10.1159/000095865.CrossRefPubMed

Hyung SM, Kim SK: Mid-term effects of trabeculectomy with mitomycin C in neovascular glaucoma patients. Korean J Ophthalmol. 2001, 15: 98-106.CrossRefPubMed

Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC: Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001, 108: 1767-1776. 10.1016/S0161-6420(01)00775-8.CrossRefPubMed

Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP: Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998, 105: 232-237. 10.1016/S0161-6420(98)92782-8.CrossRefPubMed

Lim TH, Bae SH, Cho YJ, Lee JH, Kim HK, Sohn YH: Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. Korean J Ophthalmol. 2009, 23: 188-192. 10.3341/kjo.2009.23.3.188.CrossRefPubMedPubMedCentral

Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, Otori Y, Kamei M, Kusaka S, Tano Y: Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008, 115: 1571-1580. 10.1016/j.ophtha.2008.02.026.CrossRefPubMed

Kubota T, Aoki R, Harada Y, Tou N, Tawara A: Intravitreal injection of bevacizumab to treat neovascular glaucoma. Jpn J Ophthalmol. 2008, 52: 410-412. 10.1007/s10384-008-0573-3.CrossRefPubMed

10.

Wolf A, Von Jagow B, Ulbig M, Haritoglou C: Intracameral injection of bevacizumab for the treatment of neovascular glaucoma. Ophthalmologica. 2008, 226: 51-56.CrossRef

11.

Vasudev D, Blair MP, Galasso J, Kapur R, Vajaranant T: Intravitreal bevacizumab for neovascular glaucoma. J Ocul Pharmacol Ther. 2009, 25: 453-458. 10.1089/jop.2009.0036.CrossRefPubMedPubMedCentral

12.

Beutel J, Peters S, Luke M, Aisenbrey S, Szurman P, Spitzer MS, Yoeruek E, Grisanti S: Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol. 2010, 88: 103-109. 10.1111/j.1755-3768.2008.01355.x.CrossRefPubMed

13.

Ishibashi S, Tawara A, Sohma R, Kubota T, Toh N: Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection. Arch Ophthalmol. 2010, 128: 1539-1545. 10.1001/archophthalmol.2010.282.CrossRefPubMed

14.

Yoshida N, Hisatomi T, Ikeda Y, Kohno R, Murakami Y, Imaki H, Ueno A, Fujisawa K, Ishibashi T: Intravitreal bevacizumab treatment for neovascular glaucoma: histopathological analysis of trabeculectomy specimens. Graefes Arch Clin Exp Ophthalmol. 2011, 249: 1547-1552. 10.1007/s00417-011-1761-2.CrossRefPubMed

15.

Kohno R, Hata Y, Mochizuki Y, Arita R, Kawahara S, Kita T, Miyazaki M, Hisatomi T, Ikeda Y, Aiello LP, Ishibashi T: Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol. 2010, 150: 223-229. 10.1016/j.ajo.2010.03.016.CrossRefPubMed

16.

Alkawas AA, Shahien EA, Hussein AM: Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C. J Glaucoma. 2010, 19: 622-626. 10.1097/IJG.0b013e3181ccb794.CrossRefPubMed

17.

Saito Y, Higashide T, Takeda H, Ohkubo S, Sugiyama K: Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmol. 2010, 88: 96-102. 10.1111/j.1755-3768.2009.01648.x.CrossRefPubMed

18.

Takihara Y, Inatani M, Fukushima M, Iwao K, Iwao M, Tanihara H: Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol. 2009, 147: 912-918. 10.1016/j.ajo.2008.11.015.CrossRefPubMed

19.

Rulli E, Biagioli E, Riva I, Gambirasio G, De Simone I, Floriani I, Quaranta L: Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. JAMA Ophthalmol. 2013, 131: 1573-1582. 10.1001/jamaophthalmol.2013.5059.CrossRefPubMed

20.

Takihara Y, Inatani M, Kawaji T, Fukushima M, Iwao K, Iwao M, Tanihara H: Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. J Glaucoma. 2011, 20: 196-201. 10.1097/IJG.0b013e3181d9ce12.CrossRefPubMed

21.

Sugimoto Y, Mochizuki H, Okumichi H, Takumida M, Takamatsu M, Kawamata S, Kiuchi Y: Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2010, 248: 1601-1609. 10.1007/s00417-010-1406-x.CrossRefPubMed

22.

Inoue T, Inatani M, Takihara Y, Awai-Kasaoka N, Ogata-Iwao M, Tanihara H: Prognostic risk factors for failure of trabeculectomy with mitomycin C after vitrectomy. Jpn J Ophthalmol. 2012, 56: 464-469. 10.1007/s10384-012-0171-2.CrossRefPubMed

23.

Koleva-Georgieva DN, Sivkova NP, Terzieva D: Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia Med (Plovdiv). 2011, 53: 44-50.

24.

DePalma RG, Hayes VW, Cafferata HT, Mohammadpour HA, Chow BK, Zacharski LR, Hall MR: Cytokine signatures in atherosclerotic claudicants. J Surg Res. 2003, 111: 215-221. 10.1016/S0022-4804(03)00075-1.CrossRefPubMed

25.

Cunliffe IA, Richardson PS, Rees RC, Rennie IG: Effect of TNF, IL-1, and IL-6 on the proliferation of human Tenon’s capsule fibroblasts in tissue culture. Br J Ophthalmol. 1995, 79: 590-595. 10.1136/bjo.79.6.590.CrossRefPubMedPubMedCentral

26.

Cvenkel B, Kopitar AN, Ihan A: Inflammatory molecules in aqueous humour and on ocular surface and glaucoma surgery outcome. Mediators Inflamm. 2010, 2010: 939602-CrossRefPubMedPubMedCentral

27.

Tripathi RC, Tripathi BJ, Park JK, Quaranta L, Steinspair K, Lehman E, Ernest JT: Intracameral tissue plasminogen activator for resolution of fibrin clots after glaucoma filtering procedures. Am J Ophthalmol. 1991, 111: 247-248.CrossRefPubMed

28.

Wilson RP, Lloyd J: The place of sodium hyaluronate in glaucoma surgery. Ophthalmic Surg. 1986, 17: 30-33.PubMed

29.

Elgin U, Berker N, Batman A, Simsek T, Cankaya B: Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma. J Glaucoma. 2006, 15: 466-470. 10.1097/01.ijg.0000212270.27359.64.CrossRefPubMed

30.

Good TJ, Kahook MY: Assessment of bleb morphologic features and postoperative outcomes after Ex-PRESS drainage device implantation versus trabeculectomy. Am J Ophthalmol. 2011, 151: 507-513. 10.1016/j.ajo.2010.09.004.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2415/14/55/prepub

Title: Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis
Authors: Shunji Nakatake
Shigeo Yoshida
Shintaro Nakao
Ryoichi Arita
Miho Yasuda
Takeshi Kita
Hiroshi Enaida
Yuji Ohshima
Tatsuro Ishibashi
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Ophthalmology / Issue 1/2014
Electronic ISSN: 1471-2415
DOI: https://doi.org/10.1186/1471-2415-14-55

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report

Overexpression p21WAF1/CIP1 in suppressing retinal pigment epithelial cells and progression of proliferative vitreoretinopathy via inhibition CDK2 and cyclin E

Acquired focal choroidal excavation associated with multiple evanescent white dot syndrome: observations at onset and a pathogenic hypothesis

Retinal artery occlusion as the manifestation of left atrial myxoma: a case report

Lying-down nystagmus and head-bending nystagmus in horizontal semicircular canal benign paroxysmal positional vertigo: are they useful for lateralization?

Anterior segment dysgenesis associated with Williams-Beuren syndrome: a case report and review of the literature